Jasper Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| JSPRW | GUD.TO | IMCR | CLYM | KRYS | ABCL | |
|---|---|---|---|---|---|---|
| Market cap | — | 1.09B | 1.51B | 562.59M | 9.43B | 3.86B |
| P/E (TTM) | — | 74.0 | — | — | 39.9 | — |
| Forward P/E | — | 42.7 | -39.0 | -9.8 | 35.2 | -15.6 |
| Price/book | 0.0 | 1.4 | 3.6 | 2.3 | 6.9 | 4.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | — | +87.76% | −13.38% | +323.28% | +61.55% | +101.37% |
| Today | −84.62% | +0.54% | −0.27% | −0.25% | +0.64% | +0.84% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All JSPRW news ›Jasper Therapeutics Completes IgA Nephropathy Enrollment for KP104 Phase 2 Study
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Jasper Therapeutics Completes IgA Nephropathy Enrollment for KP104…
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
Profusa Receives ISO 13485:2016 Certificate from GMED The kidney-disease study is expanding beyond IgA nephropathy, with first-patient dosing in an additional cohort anticipated in early 2027. Jasper expects initial interim IgA nephropathy…
Jasper Therapeutics registers up to 284M resale shares
Stockholders approved an amendment allowing a 1-for-15 to 1-for-35 reverse split; the board may effect it on or before December 31, 2026. After the earlier of approval or the 12-month anniversary, holders can require cash at fair value if…
Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at William Blair
Posted by Kim Johansen on Oct 14th, 2026 Equities researchers at William Blair started coverage on shares of Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) in a report issued on Wednesday. The brokerage set an “outperform” rating on…
Jasper Therapeutics asks to issue up to 604M shares
Ericsson reports third quarter results 2026 The board recommends FOR votes on all four proposals; stockholders are not being asked to approve the already completed merger. Jasper Therapeutics, Inc. seeks approval to issue common shares…
Jasper Therapeutics offers $0.324 cash per warrant
The Warrants were issued as part of Jasper Therapeutics' September 18, 2025 underwritten public offering. As filed with the Securities and Exchange Commission on October 7, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,…
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Tendered warrants will be cancelled; purchasing all outstanding warrants would require approximately $4.0 million from cash on hand. Jasper Therapeutics (JSPR) commenced an offer to purchase all outstanding warrants issued in its September…
Jasper Therapeutics: $207M illustrative 2025 net loss
CVR holders may receive a pro-rata portion of $30.0 million if FDA issues a briquilimab Priority Review Voucher on or before December 31, 2028. The pro forma records a $1.5 million change-of-control fee and shows combined cash of $142,828…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
stocktitan.net8
-
globenewswire.com1
-
themarketsdaily.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.